APMA News - November/December 2021 - 23

SPECIAL CORPORATE SECTION
Corporate Partner Perspectives 2021
APMA asked some of our top sponsors and longtime partners
why they support the association and how critical the
role of APMA members is in helping them achieve their goal
of serving the podiatric medical community. The responses
we received show their dedication, commitment, and gratitude
for all that you do as a member of APMA and as a podiatrist
leading the industry to higher heights.
Bako Diagnostics
" On behalf of the entire team at Bako Diagnostics, we thank
APMA for continued leadership in serving the needs of the
podiatric medical community. For well over a decade, our
partnership with APMA has fortifi ed our mission to provide
industry-leading diagnostic services, innovation, and continued
education. " -Wayne L. Bakotic, DO, Co-Founder and
Chief Medical Offi cer
Gebauer Company
" Gebauer has been a longtime partner and supporter of
APMA. Now more than ever, we are thankful for your loyalty
and service. Gebauer Company has been supplying ethyl
chloride topical anesthetic spray for over 120 years, and we
continue to prioritize safety, quality, and patient comfort, just
as the members of APMA do. " -Tim Mauk, Marketing Associate
Manager
Gordon Laboratories
" Gordon Laboratories is proud to be a corporate partner of
APMA. As manufacturers of the fi rst specialty line of topical
pharmaceuticals for the profession, and taking a strong supportive
role in introducing in-offi ce dispensing, we strive
with APMA in helping to lead podiatry into the 21st century. "
-SuEllen Dercher, President
Heron Therapeutics
" Heron is proud to work with APMA to improve the postoperative
pain management landscape and reduce opioid overreliance.
Reaching the majority of podiatrists in the United
States, APMA is a leading voice for foot and ankle surgery and
shares our passion for educating the industry about opioid
use, abuse, and reduction. With the introduction of our
non-opioid alternative to manage postoperative pain, we are
looking forward to collaborating with APMA in our ongoing
efforts that benefi t podiatrists and patients alike. APMA continues
to be an accommodating and responsive association to
APMA News November/December 2021 23
work alongside. " -Jessica Applonie, Senior Coordinator,
Marketing Operations
Hexima Limited
" Hexima is developing pezadeftide as a new prescription topical
product for the treatment of onychomycosis, and we are
looking to expand our relationship with APMA and practicing
podiatrists across the US. We believe that by working
closely together, there is a real potential for us to deliver a
new standard of care for the treatment of onychomycosis.
More importantly, we envision the opportunity to be truly
additive to APMA's mission to provide resources that continually
improve patient care and outcomes. Visit https://hexima.com.au. "
-Michael Aldridge, CEO and Managing Director,
Hexima Limited
Continued on page 24
Have a gripe?
A compliment? A response?
A question? Share it with us!
APMA News accepts letters to the
editor. If you have something to say
and would like your letter to be
considered for publication, contact
Peggy Tresky at pstresky@apma.org.
https://hexima.com.au https://hexima.com.au
APMA News - November/December 2021

Table of Contents for the Digital Edition of APMA News - November/December 2021
